Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.58 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.58 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.58 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.58 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.58 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.58 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.58 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.58 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.58 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7774872 | 0.95 | CA1 (0.66) | RAB9AALDH1A1MEN1POLBGAA | |
| SCHEMBL7770155 | 0.95 | CA1 (0.66) | RAB9AALDH1A1MEN1POLBGAA | |
| SCHEMBL3918802 | 0.95 | CA1 (0.66) | RAB9AALDH1A1MEN1POLBGAA | |
| SCHEMBL3919184 | 0.95 | CA1 (0.66) | RAB9AALDH1A1MEN1POLBGAA | |
| SCHEMBL3913717 | 0.95 | CA1 (0.66) | RAB9AALDH1A1MEN1POLBGAA | |
| Selenious Acid SCHEMBL20553629 | 0.94 | RAB9A (0.57) | TP53RAB9AALDH1A1MEN1POLB | |
| SCHEMBL16013604 | 0.94 | TP53 (0.67) | TP53RAB9AALDH1A1MEN1POLB | |
| SCHEMBL7716978 | 0.94 | CA1 (0.68) | TP53RAB9AALDH1A1MEN1POLB | |
| Selenious Acid SCHEMBL20553627 | 0.91 | CA1 (0.55) | TP53RAB9AALDH1A1MEN1POLB | |
| SCHEMBL10360235 | 0.89 | CA1 (0.67) | TP53RAB9AALDH1A1MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10125160-B1 | Method of making cobalt and platinum based surfactants and using for cancer therapy | UMM-AL-QURA UNIVERSITY (SA) | 2018-11-13 | — | — | US | claimed |
| US-20180305387-A1 | METHOD OF MAKING COBALT AND PLATINUM BASED SURFACTANTS AND USING FOR CANCER THERAPY | UMM-AL-QURA UNIVERSITY (SA) | 2018-10-25 | — | — | US | claimed |
| US-10125160-B1 | Method of making cobalt and platinum based surfactants and using for cancer therapy | UMM-AL-QURA UNIVERSITY (SA) | 2018-11-13 | — | — | US | disclosed |
| US-20180305387-A1 | METHOD OF MAKING COBALT AND PLATINUM BASED SURFACTANTS AND USING FOR CANCER THERAPY | UMM-AL-QURA UNIVERSITY (SA) | 2018-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305387-A1 | METHOD OF MAKING COBALT AND PLATINUM BASED SURFACTANTS AND USING FOR CANCER THERAPY | SCLY, SELENOI, SOD1 | TP53 290/4885RAB9A 3069/4885ALDH1A1 4301/4885 |
| US-10125160-B1 | Method of making cobalt and platinum based surfactants and using for cancer therapy | SCLY, SELENOI, SOD1 | TP53 290/4885RAB9A 3069/4885ALDH1A1 4301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.